Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 4
2(50.0%)
4Total
N/A(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04735159Not ApplicableCompleted

Clinical Decision Support System (CDSS) in Neurostimulation Therapy

Role: lead

NCT03669029Phase 4Unknown

Optimization of Golimumab Treatment in Ulcerative Colitis

Role: collaborator

NCT02465008Phase 4Suspended

Analgesic Effect of Levobupivacaine in Breast Augmentation

Role: lead

NCT02226809Completed

Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit

Role: collaborator

NCT01199484Not ApplicableCompleted

Specific Oral Tolerance Induction to Cow's Milk Allergy

Role: lead

All 5 trials loaded